Last edition
News about "Guangzhou-Israel Biotechnology Fund "
GIBF Announces Investment of USD 10 Million in Nectin Therapeutics
Guangzhou-Israel Biotechnology Fund (GIBF) has invested USD 10 million in Nectin Therapeutics Ltd., a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune-oncology treatments.
Guangzhou-Israel Biotechnology Fund | 07/05/2024 | By Aishwarya | 431
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members